Baseline characteristics of study population
| . | All patients (N = 692), % . |
|---|---|
| Age, y | |
| 18-49 | 22 |
| 50-59 | 21 |
| 60-64 | 14 |
| 65-69 | 19 |
| 70-74 | 14 |
| 75-79 | 9 |
| ≥80 | 1 |
| Augmented HCT-CI | |
| 0-1 | 15 |
| 2-3 | 29 |
| 4-5 | 23 |
| ≥6 | 33 |
| 2017 ELN cytogenetic risk | |
| Favorable | 21 |
| Intermediate | 43 |
| Adverse | 36 |
| KPS | |
| >70 | 83 |
| ≤70 | 17 |
| AML composite model | |
| 0-3 | 13 |
| 4-6 | 32 |
| 7-9 | 32 |
| ≥10 | 23 |
| Diagnosis | |
| Newly diagnosed AML | 77 |
| Relapsed/refractory AML | 14 |
| High-risk MDS | 9 |
| Status posttreatment | |
| Never achieved CR | 44 |
| Achieved CR | 56 |
| . | All patients (N = 692), % . |
|---|---|
| Age, y | |
| 18-49 | 22 |
| 50-59 | 21 |
| 60-64 | 14 |
| 65-69 | 19 |
| 70-74 | 14 |
| 75-79 | 9 |
| ≥80 | 1 |
| Augmented HCT-CI | |
| 0-1 | 15 |
| 2-3 | 29 |
| 4-5 | 23 |
| ≥6 | 33 |
| 2017 ELN cytogenetic risk | |
| Favorable | 21 |
| Intermediate | 43 |
| Adverse | 36 |
| KPS | |
| >70 | 83 |
| ≤70 | 17 |
| AML composite model | |
| 0-3 | 13 |
| 4-6 | 32 |
| 7-9 | 32 |
| ≥10 | 23 |
| Diagnosis | |
| Newly diagnosed AML | 77 |
| Relapsed/refractory AML | 14 |
| High-risk MDS | 9 |
| Status posttreatment | |
| Never achieved CR | 44 |
| Achieved CR | 56 |
KPS, Karnofsky performance status.